DOP2013000116A - COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO - Google Patents

COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO

Info

Publication number
DOP2013000116A
DOP2013000116A DO2013000116A DO2013000116A DOP2013000116A DO P2013000116 A DOP2013000116 A DO P2013000116A DO 2013000116 A DO2013000116 A DO 2013000116A DO 2013000116 A DO2013000116 A DO 2013000116A DO P2013000116 A DOP2013000116 A DO P2013000116A
Authority
DO
Dominican Republic
Prior art keywords
piridin
ilo
compounds
oxazol
oxazol compounds
Prior art date
Application number
DO2013000116A
Other languages
English (en)
Inventor
La Nava Eva Maria Martin De
David Andrew Coates
Jose Alfredo Martin
Raymond Gilmour
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000116(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2013000116A publication Critical patent/DOP2013000116A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

La presente invención se refiere a compuestos de oxazolo[5,4-b]piridin-5-ilo útiles en el tratamiento de cáncer.
DO2013000116A 2010-12-03 2013-05-27 COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO DOP2013000116A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382329 2010-12-03
US201161439151P 2011-02-03 2011-02-03

Publications (1)

Publication Number Publication Date
DOP2013000116A true DOP2013000116A (es) 2014-10-31

Family

ID=46162794

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000116A DOP2013000116A (es) 2010-12-03 2013-05-27 COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO

Country Status (26)

Country Link
US (1) US8288548B2 (es)
EP (1) EP2646445B1 (es)
JP (1) JP5726321B2 (es)
KR (1) KR101514162B1 (es)
CN (1) CN103221415B (es)
AR (1) AR083868A1 (es)
AU (1) AU2011337033A1 (es)
BR (1) BR112013013282A2 (es)
CA (1) CA2819822C (es)
CL (1) CL2013001518A1 (es)
CO (1) CO6761387A2 (es)
CR (1) CR20130182A (es)
DO (1) DOP2013000116A (es)
EA (1) EA021241B1 (es)
EC (1) ECSP13012653A (es)
ES (1) ES2567271T3 (es)
GT (1) GT201300139A (es)
IL (1) IL226054A0 (es)
MX (1) MX2013006184A (es)
NZ (1) NZ610289A (es)
PE (1) PE20140008A1 (es)
SG (1) SG190680A1 (es)
TW (1) TWI410425B (es)
UA (1) UA109677C2 (es)
WO (1) WO2012074761A1 (es)
ZA (1) ZA201303580B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102279347B1 (ko) 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN114732910A (zh) 2017-10-05 2022-07-12 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1255752E (pt) 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
AR029803A1 (es) * 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
CA2440211A1 (en) * 2001-03-09 2002-09-19 Pfizer Products Inc. Benzimidazole anti-inflammatory compounds
ATE343572T1 (de) * 2002-08-09 2006-11-15 Lilly Co Eli Benzimidazole und benzothiazole als inhibitoren der map-kinase
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
US7452887B2 (en) 2004-06-04 2008-11-18 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
AU2008282728B2 (en) 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use

Also Published As

Publication number Publication date
CA2819822C (en) 2015-07-21
CL2013001518A1 (es) 2013-11-04
EP2646445A1 (en) 2013-10-09
CR20130182A (es) 2013-07-09
SG190680A1 (en) 2013-07-31
BR112013013282A2 (pt) 2016-09-06
WO2012074761A1 (en) 2012-06-07
US8288548B2 (en) 2012-10-16
KR101514162B1 (ko) 2015-04-21
ZA201303580B (en) 2014-12-23
AR083868A1 (es) 2013-03-27
GT201300139A (es) 2014-04-08
IL226054A0 (en) 2013-06-27
ES2567271T3 (es) 2016-04-21
US20120142724A1 (en) 2012-06-07
MX2013006184A (es) 2013-07-15
KR20130093140A (ko) 2013-08-21
AU2011337033A1 (en) 2013-07-18
TWI410425B (zh) 2013-10-01
CA2819822A1 (en) 2012-06-07
CO6761387A2 (es) 2013-09-30
JP5726321B2 (ja) 2015-05-27
UA109677C2 (ru) 2015-09-25
CN103221415A (zh) 2013-07-24
NZ610289A (en) 2015-07-31
TW201300397A (zh) 2013-01-01
PE20140008A1 (es) 2014-01-31
EP2646445B1 (en) 2016-03-16
ECSP13012653A (es) 2013-08-30
EA021241B1 (ru) 2015-05-29
CN103221415B (zh) 2015-06-17
JP2013544835A (ja) 2013-12-19
EA201390620A1 (ru) 2013-10-30

Similar Documents

Publication Publication Date Title
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
CL2016001733A1 (es) Compuestos intermediarios para la preparación de compuestos derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer div. sol. 3415-12.
ECSP11011441A (es) Compuestos vinil indazolilo
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CR20130539A (es) Triazolopiridinas
AR091837A1 (es) Compuestos para inmunoterapia dirigida
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
AP2011005807A0 (en) 3H-imidazo[4,5-C] pyridine-6-carboxamides as anti-inflammatory agents.
BRPI0919292A2 (pt) 3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
AU2012213775A8 (en) 7-azaindole derivatives
NI201100155A (es) Composiciones y métodos para el tratamiento prolongado con aminopiridinas
CR20110427A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata
IL229993A (en) 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2
BR112012019302A2 (pt) imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met
CR20130041A (es) ISOXAZOLO[5,4-b]PIRIDINAS HERBICIDAS
UY34349A (es) OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO
DOP2013000116A (es) COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO
CL2013001445A1 (es) Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer.
ECSP10010721A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
BR112013000941A2 (pt) formulações de 14-epi-análogos de vitamina d
CR20140545A (es) Piperazino[1,2-a]indol-1-onas y [1,4]diazepino [1,2-a]indol-1-ona
CR20130005A (es) Agentes terapéuticos 976
UY34433A (es) Compuestos antimicrobianos con carbolina
PA8846601A1 (es) Tratamiento de infecciones bacterianas intracelulares